Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAF Mutation”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270
What this trial is testing

Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Verastem, Inc. 225
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Early research (Phase 1)Study completedNCT01155453
What this trial is testing

Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Who this might be right for
Advanced and Selected Solid Tumors
Novartis Pharmaceuticals 113
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Ended earlyNCT04198818
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Who this might be right for
Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more
Haihe Biopharma Co., Ltd. 37
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Testing effectiveness (Phase 2)Ended earlyNCT01514864
What this trial is testing

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Who this might be right for
Carcinoma, Non-small Cell Lung
Bristol-Myers Squibb 19
Not applicableStudy completedNCT01720758
What this trial is testing

Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease

Who this might be right for
Hairy Cell LeukemiaSplenic Marginal Zone Lymphoma
HaEmek Medical Center, Israel 20
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Testing effectiveness (Phase 2)UnknownNCT02968303
What this trial is testing

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Who this might be right for
Melanoma, Malignant, of Soft Parts
Radboud University Medical Center 200
Not applicableStudy completedNCT04236102
What this trial is testing

KEBI-Cyto Study - Use of the Biocartis Idylla

Who this might be right for
Pancreatic AdenocarcinomaLung Cancer
Royal Cornwall Hospitals Trust 55
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Not applicableUnknownNCT06081270
What this trial is testing

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer

Who this might be right for
Lung Cancer
University of Milano Bicocca 20
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Active Not RecruitingNCT05068752
What this trial is testing

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Who this might be right for
Pancreas Cancer
HonorHealth Research Institute 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 140
Not applicableApproved For MarketingNCT05760586
What this trial is testing

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Who this might be right for
Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Testing effectiveness (Phase 2)Study completedNCT01781026
What this trial is testing

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

Who this might be right for
Melanoma
Yale University 2
Testing effectiveness (Phase 2)Ended earlyNCT04585815
What this trial is testing

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 34
Load More Results